Change font size Change contrast

David Fellows – Chairman

David is Chief Executive Officer of NightstaRx Ltd. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise and Regional President at Allergan plc. David is Chairman of Oxular Limited and is a board member of NightstaRx Limited and the Glaucoma Foundation. Read more

Thomas Cavanagh – Director and CEO

Thomas is a co-founder, the Chief Executive Officer and a Board member of Oxular Limited. He is an experienced and successful entrepreneur who has helped to build four previous private equity-backed ventures. He was formerly co-founder and President of Aciex Therapeutics, where he brought its lead programme to NDA, oversaw development of a novel API technology which became the basis for future pipeline products and led a successful M&A transaction in 2014. View our team page

Ronald Yamamoto – Director and CSO

Ronald is a co-founder, the Chief Scientific Officer and a Board member of Oxular Limited. He brings more than 30 years of medical device and drug product development experience. Ronald has developed novel ophthalmic microcatheters for surgical treatment of glaucoma and retinal disease, sub-retinal access devices, diagnostic microspheres and drug-releasing implants. He was previously a co-founder and Chief Scientific Officer of iScience Interventional. View our team page

Dina Chaya – Director

Dina is a partner with NeoMed. She was previously at 3i plc in London and Index Ventures in Geneva and has worked in the private equity and venture capital healthcare industry in Europe and the US since 2001. Dina is a Board member of Oxular Limited, TopiVert Ltd and Wilson Therapeutics AB. Read more

Christina Takke – Director

Christina is co-founder and Managing Director of V-Bio Ventures. Christina was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina is a Board member of Oxular Limited and Confo Therapeutics NV. Read more

Bobby Soni – Director

Bobby is Director of Healthcare Investments at Touchstone Innovations plc. He was previously Investment Director of Novo Seeds where he led and managed investments in several seed stage companies including Acesion, Avilex, RSPR Pharma, and Contera Pharma. Bobby is a board member of Oxular Limited, Pulmocide, Artios Pharma, Autifony, Storm Therapeutics, Mission Therapeutics and Enterprise Therapeutic. Read more

Paul Hayes – Director

Paul is Chief Financial Officer of Consort Medical. He was previously Group Finance Director of Vitec Group plc and Group Financial Controller at Signet Jewelers Limited. Paul is a board member of Oxular Limited. Read more